openPR Logo
Press release

Pulmonary Drug Delivery Systems Market: is forecast to reach by 2017 - 2019

06-19-2018 05:16 PM CET | Health & Medicine

Press release from: Transparency Market Research

Pulmonary Drug Delivery Systems Market: is forecast to reach

Pulmonary Drug Delivery Systems Market: Snapshot

Pulmonary drug delivery systems refer to the technologies that are used to treat diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis using pulmonary route of drug administration. While these systems have been in medical use for more than six decades, recent technological advancements in pulmonary drug delivery systems have expanded their potential application in other diseases as well including diabetes, lung cancer, and others. The market for pulmonary drug delivery systems is projected to be worth US$28.7 bn by the end of 2019, propagating at a notable CAGR of 4.4% during the forecast period of 2017 to 2019.

Apart from growing adoption of pulmonary drug delivery as an alternative to route of drug delivery, the market is gaining traction from some of the other factors such as the development of smart and digital inhalers, increasing number of smokers, and growth of the distribution network since the emergence of ecommerce. On the flip side, regulatory hurdles, patent expiration of some of the blockbuster drugs, and issues pertaining to the stability of drugs are some of the restraints hindering the prosperity of the global pulmonary drug delivery systems market. However, the vendors of this market are expected to gain vast new opportunities in the emerging economies of Asia Pacific.

Get PDF Brochure of Report:

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=873

Metered Dore Inhalers Market’s Key Product Segment

On the basis of product type, the pulmonary drug delivery devices market has been segmented into nebulizers, metered dose inhalers (MDI), and dry powder inhaler (DPI). As of 2017, the MDI segment has the maximum demand, providing for a revenue of US$14,512.7 mn. MDIs can be further classified into three categories based on the drugs delivered, namely metered dose inhalers with bronchodilators, corticosteroids, and a combination of both. However, patents of blockbuster drugs such as Advair HFA/Seretide Evohaler and Ventolin HFA/Ventolin Evohaler by GlaxoSmithKline have expired in 2017 and is expected to reflect negatively over the MDI segment. On the other hand, the demand for nebulizers and DPIs have been anticipated multiply profitably during the forecast period of 2017 to 2019.

The report also classifies the pulmonary drug delivery systems market on the basis of application, into COPD, cystic fibrosis, and asthama. The latter provided for a demand worth of US$16,085.9 mn in 2017 and is projected to remain most profitable over the course of next seven years. The analysts of the report have also bifurcated the market on the basis of distribution channel into hospital pharmacies, retail pharmacies, and ecommerce.

Get Sample Copy of The Report:

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=873

Developed and Developing Economies Driving Demand

In terms of region, North America, Europe, and Asia Pacific are the three regions of greatest potential. According to the analysts, the North America pulmonary drug delivery systems market was worth US$10,072.8 mn, gaining traction from factors such as strong prevalence of asthma, consistent focus of the government to reduce treatment costs, and escalating percentage of geriatrics in the U.S. The European market for pulmonary drug delivery systems, which was valued at US$7,059.0 mn in 2017, is driven by the countries of Germany, France, the U.K., Italy, and Spain. Some of the major factors responsible for this stunted growth in Europe include active penetration by generic makers and government austerity measures in key countries to reduce prices. Vastly populated region of Asia Pacific, driven by the emerging economies of China and India, is expected to generate demand for pulmonary drug delivery devices at a robust rate during the forecast period of this report.

AstraZeneca Plc, Novartis AG, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc, Merck & Co. Inc., and Teva Pharmaceutical Industries Ltd. are a few key players operating in the global pulmonary drug delivery systems market.

Get Discount –

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=873

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports

Contact Us

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pulmonary Drug Delivery Systems Market: is forecast to reach by 2017 - 2019 here

News-ID: 1089168 • Views: 282

More Releases from Transparency Market Research

Impact of Outbreak of COVID-19 on Medical Education Market : Global Industry Ana …
Transparency Market Research (TMR) has published a new report on the medical education market for the period of 2019–2027. According to the report, the global medical education market was valued at nearly US$ 31 Bn in 2018, and is projected to expand at a CAGR of more than 4% from 2019 to 2027. Rise in the number of medical schools and increase in cost of medical education are the
Healthcare BI Platform Market Companies Analysis, Advancement and Precise Outloo …
In an intensely competitive healthcare business intelligence (BI) platform market, large players are aggressively focused on expanding their geographical outreach, says Transparency Market Research (TMR) in a new market intelligence report. These large players are leveraging the cloud business model to provide healthcare BI solutions that can be accessed irrespective of location. Apart from this, savvy players are entering into partnerships with hospital groups and healthcare bodies to integrate healthcare BI
Substance Abuse Treatment Market News Research Report 2024
A recent report by Transparency Market Research on the substance abuse treatment market in the U.S. states that the competitive landscape is highly fragmented. This is because around 242 companies compete against one another in it. This also makes overall competition stiff. Some of the companies that have beat competition to emerge as leading players in the market are Pfizer Inc., Alkermes Plc, GlaxoSmithKline Plc., and Purdue Pharma LP. Their
Clinical Oncology Next Generation Sequencing Market is Thriving Worldwide By Siz …
Clinical Oncology Next Generation Sequencing: Introduction Next generation sequencing for tumor and germline DNA is required for oncology screening for therapeutic application. Rise in burden of cancer increases the need for early detection of the condition to carry out the generate target therapy. Companies are investing to develop technologically advanced devices/solutions for precision detection. In 2012, Oxford Nanopore had launched the GridION sequencing platform, which can sequence a human genome in 15

All 5 Releases


More Releases for Pulmonary

Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary Drugs Market – Boon for Diseased Lungs Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated
Global Pulmonary Arterial Hypertension Market to 2024
Global Pulmonary Arterial Hypertension (PAH) market was valued at $5.0bn in 2015 and is forecast to grow at a modest 6.0% CAGR between 2015 and 2024, to result in 2024 global sales of $9.0bn. PAH is broadly split into two classes, primary or secondary. Primary pulmonary hypertension (PPH) refers to pulmonary hypertension occurring without an identifiable cause. Secondary pulmonary arterial hypertension (PAH) occurs in association with some other identifiable medical condition.
Pulmonary Fibrosis Market Professional Survey Report 2017
Global Pulmonary Fibrosis Market: Snapshot Pulmonary fibrosis belongs to the family of interstitial diseases that can lead to damage of the lungs. As the lung tissue becomes stiff and thickened, it interferes with a person’s ability to breathe. The scarring of lung tissues is associated with a multitude of factors. However, in most cases, the cause of the problem can’t be determined. This state is termed as idiopathic pulmonary fibrosis. While the
Pulmonary Drugs 2024 Market Research Report
Global Pulmonary Drugs Market: Snapshot The global pulmonary drugs market has been the key area of focus and the most crucial market for the healthcare industry in the last couple of years. However, the market is expected to witness a significant decline over the forecast period with a -6.3% CAGR from 2016 to 2024. The market is anticipated to fall to US$28,082.1 mn from a valuation of US$48,039.7 mn in
Latest Report: Global Pulmonary Hypertension Market
MarketResearchReports.Biz presents this most up-to-date research on "Pulmonary Hypertension-Pipeline Insights, 2017" DelveInsights, Pulmonary Hypertension-Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Pulmonary Hypertension. The DelveInsightsReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations,